These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 12908845)
1. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Borges N Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845 [TBL] [Abstract][Full Text] [Related]
2. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Borges N Expert Opin Drug Saf; 2005 Jan; 4(1):69-73. PubMed ID: 15709899 [TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Deane KH; Spieker S; Clarke CE Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119 [TBL] [Abstract][Full Text] [Related]
4. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease. Benabou R; Waters C Expert Opin Drug Saf; 2003 May; 2(3):263-7. PubMed ID: 12904105 [TBL] [Abstract][Full Text] [Related]
5. Role of tolcapone in the treatment of Parkinson's disease. Leegwater-Kim J; Waters C Expert Rev Neurother; 2007 Dec; 7(12):1649-57. PubMed ID: 18052761 [TBL] [Abstract][Full Text] [Related]
6. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. Deane KH; Spieker S; Clarke CE Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118 [TBL] [Abstract][Full Text] [Related]
7. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis. Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736 [TBL] [Abstract][Full Text] [Related]
8. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease. Sabaté M; Bosch A; Pedrós C; Figueras A Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327 [No Abstract] [Full Text] [Related]
9. Tolcapone: a novel approach to Parkinson's disease. Micek ST; Ernst ME Am J Health Syst Pharm; 1999 Nov; 56(21):2195-205. PubMed ID: 10565698 [TBL] [Abstract][Full Text] [Related]
10. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group. Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521 [TBL] [Abstract][Full Text] [Related]
11. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084 [TBL] [Abstract][Full Text] [Related]
12. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of tolcapone in Parkinson's disease: systematic review. Artusi CA; Sarro L; Imbalzano G; Fabbri M; Lopiano L Eur J Clin Pharmacol; 2021 Jun; 77(6):817-829. PubMed ID: 33415500 [TBL] [Abstract][Full Text] [Related]
14. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522 [TBL] [Abstract][Full Text] [Related]